Christine Lindenboom | Vice President-Investor Relations and Corporate Communications |
John Maraganore | Chief Executive Officer |
Barry Greene | President |
Pushkal Garg | Chief Medical Officer |
Jeff Poulton | Chief Financial Officer |
Yvonne Greenstreet | Chief Operating Officer |
Emma Nealon | Cantor Fitzgerald & Co. |
Salveen Richter | Goldman Sachs |
David Lebowitz | Morgan Stanley |
Do Kim | BMO Capital Markets. |
Ritu Baral | Cowen |
Paul Matteis | Stifel |
Maury Raycroft | Jefferies |
Anupam Rama | JP Morgan |
Leland Gershell | Oppenheimer |
Ladies and gentlemen, thank you for standing-by and welcome to the Alnylam Pharmaceuticals Conference Call to discuss Fourth Quarter and Year End 2019 Financial Results [Operator Instructions] Please be advised that this call is being taped at the company’s request.
I would now like to turn the call over to the company.
Good morning. I’m Christine Lindenboom, Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, Chief Executive Officer; Barry Greene, President; Pushkal Garg, Chief Medical Officer; Jeff Poulton, Chief Financial Officer; and Yvonne Greenstreet, Chief Operating Officer.